Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.

ABSTRACT:

Aim

To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC).

Methods and results

Sixty-seven patients with unresectable advanced HCC (u-HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression-free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; ha

SUBMITTER: Tomonari T 

PROVIDER: S-EPMC8593789 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature